202 3 年度報 告 Annual Report 賽生藥業控股有限公司 * SciClone Pharmaceuticals (Holdings) Limited C122893 賽生藥業控股有限公 司 * SciClone Pharmaceuticals (Holdings) Limited 股份代號 Stock Code: 6600 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) 2023 年度報 告 Annual Report *僅供識別 For identification purpose only 目錄 公司資料 Corporate information 2 主席報告 Chairman's statement 4 管理層討論及分析 Management discussion and analysis 22 董事及高級管理層履歷 Biographies of director and senior management 31 企業管治報告 Corporate governance report ...

智通财经APP讯，赛生药业(06600)及要约人Silver Pegasus Investment Limited 联合公布，于2024年3月19 日，要约人就根据公司法第86条以协议安排方式将公司私有化，要求董事会向计划股份持有人提呈建 议，其中涉及注销计划股份，作为代价，就每股计划股份以现金向计划股东支付注销价，并撤销股份于 联交所的上市地位。 每股计划股份现金18.8港元较不受干扰日期(2024年3月15日)在联交所所报收市价每股14.04港元溢价约 33.90%，较最后交易日(2024年3月18日)在联交所所报收市价每股16.04港元溢价约17.21%。 最后交易日的交易量为974.15万股。不受干扰期间的平均每日交易量为 203.47万股。公司股价在最后交 易日上涨14.25%。相比之下，恒生指数在最后交易日上涨0.10%。 计划生效后，所有计划股份将予注销，且计划股份的任何股份证书于其后将不再具有所有权文件或证据 的效力。公司将于计划生效后立即根据上市规则第6.15(2)条向联交所申请撤销股份于联交所的上市地 位。 自公司首次公开发售以来，多项因素导致资本市场及公司股价受压，包括地缘局势紧张、供应 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 SciClone Pharmaceuticals (Holdings) Limited 賽 生 藥 業 控 股 有 限 公 司 * （於開曼群島註冊成立的有限公司） （股份代號：6600） 截至2023年12月31日止年度的年度業績公告 賽生藥業控股有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司及其附 屬公司（「本集團」或「我們」）截至2023年12月31日止年度的經審核綜合業績。該 等業績已經本公司核數師按照國際審計準則審核。此外，該業績亦經本公司審 核委員會審閱。 | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

智通财经APP讯，赛生药业(06600)发布公告，新型抗菌药物Vaborem®(注射用美罗培南韦博巴坦) (Vaborem®)在中国开展的III期临床试验已成功完成全部受试者入组。 该研究是在中国正开展的一项随机、双盲双模拟、阳性药物对照、多中心的III期临床试验，旨在评价 Vaborem®在复杂性尿路感染"cUTI")(包括急性肾盂肾炎)患者中的有效性和安全性，由復旦大学附属华 山医院王明贵教授和上海交通大学医学院附属仁济医院郑军华教授担任主要研究者，在全国27家研究中 心共入组了108例受试者。该研究结果以及同时开展的一项在中国健康志愿者中评估Vaborem®药代动力 学特征的研究结果，将用于桥接国外临床试验数据，并最终支持Vaborem®在中国的上市申请。 Vaborem®为碳青霉烯类抗菌药物以及A类及C类丝氨酸酶β内醯胺酶的新型苯硼酸β-内醯胺酶抑制剂的 固定剂量组合。韦博巴坦能够抑制多种A类以及C类β-内醯胺酶，其保护美罗培南免受丝氨酸酶碳青霉 烯酶的降解，恢复美罗培南对碳青霉烯类耐药菌株的活性。Vaborem®被专门开发用于抑制碳青霉烯类 耐药肠桿菌科细菌(CRE)，包括常见的产肺炎克雷伯菌碳青霉 ...

Financial Performance - For the six months ended June 30, 2023, the company achieved revenue of RMB1,603.3 million, an increase of 8.7% compared to the same period last year[13]. - Gross profit for the first half of 2023 grew to RMB1,194.7 million, reflecting a 5.3% increase from the first half of 2022[13]. - Net profit increased by 18.4% to RMB630.2 million compared to the net profit for the six months ended June 30, 2022[13]. - Operating cash flow reached RMB579.7 million, which is RMB55.8 million or 10.6% higher than the same period last year[13]. - The Company’s operating profit for the first half of 2023 was RMB694.8 million, a 18.3% increase from RMB587.2 million in the same period of 2022[63]. - Profit for the period was RMB630.2 million in the first half of 2023, up by 18.4% from RMB532.2 million for the same period last year[82]. - Total assets declined to RMB4,179.1 million as of June 30, 2023, from RMB4,320.4 million as of December 31, 2022[85]. - Total liabilities slightly increased to RMB1,365.1 million as of June 30, 2023, from RMB1,328.2 million as of December 31, 2022[85]. Expenses and Costs - Selling and marketing expenses increased by 16.8%, while research and development expenses grew by 45.4% compared to the previous year[14]. - The cost of revenue increased by 19.8% to RMB408.6 million in the first half of 2023, primarily due to a significant rise in product costs amounting to RMB51.9 million[72]. - Administrative expenses decreased by 34.2% to RMB62.7 million in the first half of 2023 from RMB95.3 million for the same period last year[81]. - Research and development expenses increased to RMB72.7 million, representing 4.5% of total revenue, compared to 3.4% in the previous year[63]. - Product costs accounted for 64.7% of total revenue in the first half of 2023, up from 62.3% in the same period last year[76]. Product Development and Clinical Research - The company is sponsoring over 10 ongoing clinical studies in China and overseas (the U.S. and Italy) to explore the potential clinical applications of its marketed products in oncology, severe infections, vaccines, and other therapeutic areas[30]. - Results from two clinical trials of Thymosin α-1 ("Tα1") were presented at the 2023 American Society of Clinical Oncology ("ASCO") Annual Meeting, highlighting its safety and efficacy in patients with advanced solid tumors and its integration into concurrent chemoradiotherapy[32]. - Tα1 has been included in more than 25 treatment guidelines and consensuses since 2014, indicating its recognized importance in clinical practice[36]. - A randomized controlled trial (RCT) for sepsis involving 1,106 patients is in preparation for publication, showcasing the company's commitment to advancing clinical research[34]. - The integration of Tα1 into treatment regimens has shown potential for improving survival outcomes in patients with locally advanced non-small cell lung cancer (LA-NSCLC) when combined with concurrent chemoradiotherapy[32]. Market and Sales Strategy - The company is actively searching for potential merger and acquisition targets to support growth[15]. - The upgrade of the "Go-To-Patient" model to version 6.2 aims to enhance digital commercialization capabilities and product accessibility[14]. - As of June 30, 2023, sales through the GTP model accounted for over 78% of total sales volume of Zadaxin, up from approximately 72% in the same period last year[23]. - The GTP model has been instrumental in diversifying sales channels by extending Zadaxin's sales from hospitals to pharmacies since its pilot in 2015[22]. - The company aims to enhance long-term brand loyalty through value-added services on the Hi-Doctor Platform, which provides comprehensive academic and patient education[24]. Financial Position and Cash Management - As of June 30, 2023, total cash and cash equivalents amounted to approximately RMB2.3 billion, representing about 83.3% of the company's net assets[15]. - The ratio of total borrowings to total assets remained healthy at 20.7%[15]. - Total borrowings were approximately RMB863.8 million as of June 30, 2023, all denominated in USD[87]. - The company's gearing ratio was 32.7%, an increase from 30.7% as of December 31, 2022[89]. Shareholder and Corporate Governance - The Board has resolved not to pay any interim dividend for the six months ended June 30, 2023, compared to nil for the same period in 2022[106]. - The company complied with all applicable code provisions of the Corporate Governance Code during the six months ended June 30, 2023[98]. - The Audit Committee reviewed the unaudited condensed consolidated results for the six months ended June 30, 2023[101]. - The company is committed to refining its remuneration and incentive policies to ensure competitive remuneration packages for employees[92]. Employee and Incentive Plans - The Option Incentive Plan aims to provide performance-driven incentives to retain key talents and align the interests of employees and shareholders[145]. - The company has a structured approach for granting options, requiring board approval for the CEO and committee approval for other participants[146]. - The maximum number of shares under the Option Incentive Plan is capped at 54,778,710 shares, representing 8.08% of the total shares issued on the Listing Date[149]. - The vesting schedule for options typically spans two years from the date of grant[173]. Product Pipeline and Market Launches - The company has developed a pipeline of 9 potential drug candidates, with 5 in phase III or later stages overseas and a fast-to-market strategy in China[44]. - Danyelza was officially launched in China on July 1, 2023, with patient enrollment expected to begin in the second half of 2023[61]. - The Company successfully dosed the first subject in the Phase III clinical trial of Vaborem in early July 2023[59]. - The company is actively promoting its products through clinical studies and academic initiatives to expand their clinical adoption and sustainable growth[29].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 SciClone Pharmaceuticals (Holdings) Limited 賽 生 藥 業 控 股 有 限 公 司 * （於開曼群島註冊成立的有限公司） （股份代號：6600） 截至2023年6月30日止六個月的中期業績公告 賽生藥業控股有限公司（「本公司」或「賽生」）董事會（「董事會」）欣然宣佈本公 司及其附屬公司（「本集團」或「我們」）截至2023年6月30日止六個月（「報告期」） 的未經審核簡明綜合業績。該等中期業績已經本公司核數師按照國際審閱委 聘準則第2410號「由實體獨立核數師審閱中期財務資料」進行審閱。此外，業績 亦經本公司審核委員會審閱。 | --- | |--------------------------------------------------------------------------------------------------------------- ...

LONE® PHARMACEUTICALS 賽 生 藥 業 控 股 有 限 公 司 * SciClone Pharmaceuticals (Holdings) Limited ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) (Incorporated in the Cayman Islands with limited liability) 股份代號 Stock Code: 6600 2 000 Annual Report 年 度 報 告 『僅供識別 For identification purpose only | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------|---------|-------|-------|-------| | | | | | | | | | | | | | 目錄 | | | | | | Content | | | | | | 公司資料 Corporate information | 2 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 SciClone Pharmaceuticals (Holdings) Limited 賽 生 藥 業 控 股 有 限 公 司 * （於開曼群島註冊成立的有限公司） （股份代號：6600） 截至2022年12月31日止年度的年度業績公告 賽生藥業控股有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司及其附 屬公司（「本集團」或「我們」）截至2022年12月31日止年度的經審核綜合業績。該 等業績已經本公司核數師按照國際審計準則審核。此外，該業績亦經本公司審 核委員會審閱。 | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

SCI CLONE® PHARMACEUTICALS 賽 生 藥 業 控 股 有 限 公 司 * SciClone Pharmaceuticals (Holdings) Limited ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) (Incorporated in the Cayman Islands with limited liability) 股份代號 Stock Code: 6600 2022 Interim Report 中 期 報 告 *僅供識別 For identification purpose only 目錄 公司資料 2 Corporate information 財務摘要及業務回顧 4 Financial highlights and business review 管理層討論及分析 19 Management discussion and analysis 企業管治及其他資料 30 Corporate governance and other information 簡明合併財務報表審閱報告 54 Report on review of condensed conso ...